Success Story: Building Next-Generation Immune Therapies Supports a Successful NIW Petition

Posted by wegreened on October 15, 2026 in NIW, Biology (Pathology and Immunology, Human Genetics, Genomics, Molecular Biology, Animal, Plant, Microbiology, Genetics, Botany)

Client’s Testimonial:

“I am writing to express my heartfelt appreciation for your invaluable assistance throughout my EB-2 NIW application process. Your expertise and dedication made a significant difference in navigating the complexities of immigration law.

From our initial consultation to the final submission, your guidance was instrumental in ensuring that my application was thorough and compelling. Your attention to detail and understanding of the requirements helped me present my qualifications effectively, which I believe played a crucial role in the success of my case.”

On January 24^th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Post-doc in the field of Immunology (Approval Notice).

General Field: Immunology

Position at the Time of Case Filing: Post-doc

Country of Origin: India

State of Residence at the Time of Filing: Pennsylvania

Approval Notice Date: January 24^th, 2026

Processing Time: 2 months, 14 days (Premium Processing Requested)

Case Summary:

We supported an immunology researcher whose proposed endeavor is to develop novel therapies targeting different aspects of chronic disease pathophysiology—including cytokines, enzymes, and cellular pathways—to regulate immune cells, strengthen biomedical research infrastructure, and foster technological leadership.

A Clearly Defined Endeavor With Translational Direction

We demonstrated that the client’s work focuses on mechanism-driven immunology that can translate into more targeted therapeutic strategies. Her plans center on identifying specific molecular regulators of immune cell behavior and using advanced experimental approaches, including proteomics methods, to map how signaling pathways can be modulated for better outcomes in chronic inflammatory conditions.

A well-positioned researcher with measurable peer-validated momentum

The petition also presented objective indicators that the client is equipped to advance the endeavor. She holds a Ph.D. in Science and an M.S. in Life Science and Biotechnology, supported by a research skillset spanning advanced immunology methods and data-driven experimental systems.

Her scholarly record documented sustained output and influence, including 21 peer-reviewed journal articles, 6 conference abstracts, and 2 preprints. The case also emphasized independent reliance by the field, supported by 250 citations to her published body of work. This citation history showed that other researchers relied on the work to move their own investigations forward.

Outcome

This NIW case presented a clear chain of logic: a precisely stated immunology endeavor, a public-benefit rationale tied to chronic disease needs and U.S. biomedical leadership goals, and objective evidence of strong positioning through advanced credentials, sustained scholarly production, and fieldwide reliance. North America Immigration Law Group (Chen Immigration Law Associates) was honored to support the case by translating specialized immune-mechanism research into an adjudicator-friendly NIW narrative grounded in substantial merit, national importance, and documented momentum.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Sixty-four Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With nearly 69,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Tens of Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to nearly 69,000 in 2025.

Track Record of Success EB-1 and NIW Approvals

(2012.01 - 2025.12)

Category	Approval or Refund^®		Approval or Refiling^TM
	Approval or Refund^®
Category	Approved Sum	Success Rate	Approved Sum	Success Rate
NIW	42,047	99%	5,258	97%
EB1A	9,218	91%	4,534	86%
EB1B	1,488	98%	448	93%
Total	52,753	98%	10,240	92%